Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early‐Stage Viral Disease

Documenti analoghi

• Ablation‐Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma
  di: Kazuya Kariyama, et al.
  Pubblicazione: (2026)
• Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct‐acting antiviral agents
  di: Hideko Ohama, et al.
  Pubblicazione: (2024)
• Effect of Butyrate‐Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab
  di: Kazuhiro Nouso, et al.
  Pubblicazione: (2026)
• Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma
  di: Atsushi Naganuma, et al.
  Pubblicazione: (2025)
• Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients
  di: Takeshi Hatanaka, et al.
  Pubblicazione: (2024)